Drug Database
OF

ofloxacin (ofloxacin, Ranbaxy / Zanocin OD)

✓ Approved

Ranbaxy Laboratories Limited · Small Molecule · Small Molecule

What is ofloxacin?

ofloxacin is a small molecule developed by Ranbaxy Laboratories Limited. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namesofloxacin, Ranbaxy, Zanocin OD
CompanyRanbaxy Laboratories Limited
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Ranbaxy Laboratories Limited

Therapeutic Indications

ofloxacin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsSalmonellosis✓ Approved

Related Research Articles

PubMedThe Annals of otology, rhinology, and laryngology2026-10-18

Acute Otitis Externa-Antimicrobial Resistance in the US and Canada: Phase III Study Outcomes.

Bentley Christine C, Lückermann Mark M, Dalhoff Axel A, Vente Andreas A

The goal of this investigation was to characterize the microbiological profile and antimicrobial susceptibility patterns of pathogens isolated from AOE patients of 2 vehicle-controlled Phase III clinical trials and evaluate pathogen eradication rates achieved with finafloxacin otic suspension. In vitro MIC comparisons to other fluoroquinolones (ciprofloxacin, ofloxacin) are reported as supplementary susceptibility data and do not reflect direct randomized clinical comparisons. A total of 2683 bacteria isolated from 1234 AOE patients enrolled in 2 Phase III clinical studies in the United States, Puerto Rico, and Canada were analyzed. Specimens were collected from the external ear of subjects with AOE. Species-level identification for each bacterial isolate recovered was obtained by combining phenotypic and genotypic data. End point minimum inhibitory concentration (MIC) testing was performed using Clinical and Laboratory Standards Institute recommended methods. 72.7% of the pre-therapy bacteria were Gram-positive and 27.3% Gram-negative. Most frequent bacterial isolates were Staphylococcus spp. (46.7%) followed by Pseudomonas spp. (19.5%). Methicillin resistance was detected in 17.0% of S. aureus (MRSA) and 33.2% of S. epidermidis (MRSE) isolates. Ciprofloxacin resistance was identified in 12.5% of S. aureus and 14.0% of S. epidermidis isolates. Finafloxacin eradicated 86.4% of the MRSA isolates and 80.6% of the MRSE isolates. Finafloxacin eradicated ciprofloxacin-resistant Staphylococcus spp. in 74.4% and ciprofloxacin-resistant Pseudomonas spp. in 87.5% of treated patients. Finafloxacin demonstrated high eradication rates in AOE patients with methicillin-resistant S. epidermidis and S. aureus, as well as in patients with ciprofloxacin-resistant Staphylococcus spp.- and Pseudomonas spp., irrespective of the pathogen's resistance profile. These in vitro findings, together with observed eradication rates in the vehicle-controlled trials, suggest that finafloxacin may offer advantages in the treatment of resistant organisms, particularly under acidic pH conditions. However, direct clinical trial comparisons have not been conducted. Clinical trial registry name: ClinicalTrials.gov. URL: https://clinicaltrials.gov/. Identifier: NCT01535599 and NCT01535560.

PMID 42892712
Read full article →
PubMediScience2026-10-17

Resveratrol-mediated Fe(III)/peroxydisulfate activation for ofloxacin degradation at circumneutral pH.

Wu Yanlin Y, Yang Wenyu W, Zeng Yilan Y, Huang Dingfeng D et al.

Iron-mediated peroxydisulfate (PDS) activation is limited by slow Fe(III)/Fe(II) redox cycling under circumneutral conditions. Here, resveratrol (RES), a natural stilbene polyphenol, was introduced as a low-dose redox mediator to promote Fe(II) formation from Fe(III) for enhanced PDS activation. The Fe(III)/RES/PDS system showed higher ofloxacin (OFL) degradation than the corresponding single-reagent and binary systems and achieved approximately 90% OFL degradation at pH 6.5. Chemical quenching and competition-kinetic analysis indicated that sulfate radical (SO4 ·-) was the major contributor to OFL degradation, while hydroxyl radical (·OH) played a secondary role. Matrix experiments showed that Cl- and NO3 - had minor effects, whereas NO2 - strongly inhibited OFL degradation. This work provides a case study of RES-mediated Fe(III)/PDS activation for antibiotic degradation under near-neutral conditions.

PMID 42890338
Read full article →
PubMedMaterials (Basel, Switzerland)2026-10-16

Study on the Performance and Efficiency of MgO/CuFeO2 Composite Catalyst in Degradation of Organic Pollutants.

Li Xuanhao X, You Junhua J, Zhang Jie J

With the acceleration of industrialization and increasing human activities, antibiotic pollutants enter aquatic environments through various pathways and pose serious threats to ecological safety and human health. Ofloxacin (OFX), a typical fluoroquinolone antibiotic, is persistent in water media owing to its high chemical stability and poor biodegradability. In this study, MgO/CuFeO2-based Fenton-type composite catalysts were prepared to investigate their efficiency in removing OFX from water. Among the as-prepared materials, MgO/CuFeO2-20 wt% exhibited the optimum catalytic activity: under the conditions of 20 mg L-1 initial OFX concentration, 0.5 g L-1 catalyst dosage and 20 mM H2O2 at natural pH, it achieved approximately 95% ofloxacin removal within 120 min, with a pseudo-first-order kinetic rate constant k1 of 0.0461 min-1. Benefiting from MgO modification, the catalyst maintained high degradation efficiency over a broad pH range of 5-9 and retained satisfactory catalytic performance after five consecutive cyclic runs with only minor activity decay. Characterizations including XRD, SEM-TEM, XPS, BET, LSV-EIS and ESR-DMPO verified that the construction of tight MgO-CuFeO2 heterointerfaces accelerated interfacial electron transfer and promoted the regeneration of Cu+/Cu2+ and Fe2+/Fe3+ redox couples. Hydroxyl radicals (·OH) were identified as the dominant reactive oxygen species for pollutant oxidation. This work provides a facile modification strategy to alleviate particle aggregation and metal-ion leaching drawbacks of bare CuFeO2, offering experimental support for designing high-efficiency delafossite-based heterogeneous Fenton-like catalysts for antibiotic-containing wastewater remediation.

PMID 42882746
Read full article →
PubMedEnvironmental geochemistry and health2026-10-16

Occurrence, spatial distribution, and ecological and human health risks of antibiotic residues in the River Jhelum.

Fatima Bakhtawar B, Mahmood Aamna A, Urooj Afshan A, Waseem Ariba A et al.

Antibiotic residues in riverine environments are emerging contaminants of concern because of their persistence, ecological effects, and potential contribution to antimicrobial resistance. This study investigated the occurrence, spatial distribution, pollution status, and screening-level ecological and human-health risks of six antibiotics in the River Jhelum, Pakistan. Surface-water samples were collected from ten monitoring sites representing upstream, midstream, and downstream reaches during a post-monsoon sampling campaign. Antibiotics were quantified using High Performance Liquid Chromatography coupled with photodiode-array detection, while single-factor and comprehensive pollution indices and GIS-based spatial interpolation were applied to characterize contamination patterns. Azithromycin exhibited the highest concentration (20.30 µg/L), followed by ofloxacin (12.70 µg/L), ciprofloxacin (8.03 µg/L), linezolid (4.55 µg/L), cefixime (1.40 µg/L), and levofloxacin (0.51 µg/L). Azithromycin showed the greatest pollution burden across the monitoring sites investigated, whereas levofloxacin exhibited comparatively limited contamination. The comprehensive pollution assessment indicated substantial combined antibiotic contamination across the investigated river transect. Azithromycin produced the highest ecological risk quotient (RQ = 17.41), indicating high predicted ecological risk under the applied screening framework. Human health hazard quotients remained below unity, indicating non carcinogenic risks. These findings strengthen wastewater management, pharmaceutical discharge controls, and systematic monitoring of antibiotic residues in the River Jhelum.

PMID 42886401
Read full article →
PubMedJournal of colloid and interface science2026-10-13

Boundary unsaturated Iron coordination engineering on S-scheme heterojunctions steering selective H2O2 homolysis for enhanced Fenton-like catalysis.

Sun Zeyang Z, Wang Yan Y, Qian Kun K, Meng Suci S et al.

Redirecting photocatalytic H2O2 activation from inefficient heterolytic cleavage toward the homolytic generation of hydroxyl radicals (•OH) is paramount for maximizing oxidant utilization in photo-Fenton-like water purification. Herein, we propose a selective H2O2 homolytic activation strategy enabled by a SrFe12O19/C3N4 (SCN-50) S-scheme heterojunction synthesized via urea-assisted thermal polymerization. The engineered coordinatively unsaturated Fe sites, characterized by an upshifted d-band center, effectively diminish the thermodynamic barrier for *OH intermediate formation, thereby steering H2O2 dissociation toward the homolytic •OH pathway. Consequently, the integrated SCN-50 architecture delivers an exceptional •OH generation selectivity of 86.3%. Driven by the S-scheme internal electric field, the synergistic preservation of strongly oxidizing holes (h+) at the oxidative terminus establishes a highly efficient relay degradation network for ofloxacin (OFX). Mechanistically, initial mild oxidation initiates preliminary side-chain dismantling, whereas the abundant •OH and preserved h+ cooperatively drive subsequent ring-opening and deep degradation. SCN-50 exhibits a rapid OFX degradation rate of 0.10 min-1, surpassing pristine C3N4 and SrFe12O19 by 2.5 and 16.7 times, respectively, alongside robust stability across four batch cycles and a 100-min continuous-flow operation. This work provides profound insights into tailoring H2O2 homolysis and engineering S-scheme-driven multi-species relay degradation for environmental remediation.

PMID 42863351
Read full article →
PubMedPloS one2026-10-12

Retraction: Biogenic synthesis of ZnO and Al2O3 nanoparticles using Camellia sinensis and Origanum vulgare L. leaves extract for spectroscopic estimation of ofloxacin and ciprofloxacin in commercial formulations.

PLOS One Editors

PMID 42862777
Read full article →

+8402 more articles available with a free account

Sign up free to view all articles →

Ask about ofloxacin